Suppr超能文献

人类甲状旁腺腺瘤中9号染色体短臂DNA缺失及p16和p15细胞周期蛋白依赖性激酶抑制基因分析。

Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas.

作者信息

Tahara H, Smith A P, Gaz R D, Arnold A

机构信息

Laboratory of Endocrine Oncology, Massachusetts General Hospital, Boston 02114, USA.

出版信息

J Clin Endocrinol Metab. 1996 Oct;81(10):3663-7. doi: 10.1210/jcem.81.10.8855819.

Abstract

Rearrangement and overexpression of the PRAD1/cyclin D1 oncogene, a cell cycle regulator, have been implicated in the pathogenesis of a subset of parathyroid adenomas. Recently, two cell cycle regulators that inhibit the cyclin D1-associated kinases cdk4 and cdk6 have been identified: p16 and p15, the products of the INK4A (also known as CDKN2, MTS1) and INK4B (also known as MTS2) putative tumor suppressor genes located on 9p21. Because inactivation of the p16 or p15 genes might be expected to result in oncogenic consequences similar to those from cyclin D1 overexpression, we examined 25 parathyroid adenomas for 1) allelic loss of polymorphic DNA loci on chromosome arm 9p, 2) homozygous deletions of the p16 and p15 genes by Southern blot analysis, and 3) mutations of the p16 and p15 genes by single strand conformational polymorphism analysis. Heterozygous allelic loss at 9p was observed in 4 of 25 adenomas (16%); their smallest shared region of deletion was 9p21-pter, which includes both the p16 and p15 genes. However, single strand conformational polymorphism analysis of all 3 exons of the p16 gene and both exons of the p15 gene failed to demonstrate mutation in any of the 25 cases, and homozygous deletions of the p16 and p15 genes, which are present in some human cancers, were not found in any parathyroid tumors. These observations indicate that inactivating mutations or homozygous deletions of the p16 and p15 genes occur uncommonly, if ever, in parathyroid adenomas; however, loss of a different tumor suppressor gene (or genes) on 9p appears to contribute to the pathogenesis of a significant percentage of these tumors.

摘要

细胞周期调节因子PRAD1/细胞周期蛋白D1癌基因的重排和过表达与一部分甲状旁腺腺瘤的发病机制有关。最近,已鉴定出两种抑制细胞周期蛋白D1相关激酶cdk4和cdk6的细胞周期调节因子:p16和p15,它们分别是位于9p21的INK4A(也称为CDKN2、MTS1)和INK4B(也称为MTS2)假定肿瘤抑制基因的产物。由于预计p16或p15基因失活会导致与细胞周期蛋白D1过表达类似的致癌后果,我们检测了25例甲状旁腺腺瘤,以确定:1)9号染色体臂上多态性DNA位点的等位基因缺失;2)通过Southern印迹分析检测p16和p15基因的纯合缺失;3)通过单链构象多态性分析检测p16和p15基因的突变。在25例腺瘤中有4例(16%)观察到9p杂合性等位基因缺失;它们最小的共同缺失区域是9p21-pter,其中包括p16和p15基因。然而,对p16基因的所有3个外显子和p15基因的2个外显子进行单链构象多态性分析,在25例病例中均未发现突变,并且在任何甲状旁腺肿瘤中均未发现某些人类癌症中存在的p16和p15基因的纯合缺失。这些观察结果表明,p16和p15基因的失活突变或纯合缺失在甲状旁腺腺瘤中很少发生(如果曾经发生过的话);然而,9p上另一个(或多个)肿瘤抑制基因的缺失似乎在相当比例的这些肿瘤的发病机制中起作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验